Latest News - Zoetis
Top Corporates Hub
Zoetis
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
21.10.2026 14:31
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX
20.10.2026 13:06
Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.
FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
20.10.2026 10:09
https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-ready-use-cefovecin-injectable-treatment-certain-skin-infections-dogs
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
20.10.2026 08:22
Analysts downgraded Werner, Zoetis, Apple, Heartland Express and Elanco, cutting ratings to Neutral/Hold and lowering price targets.
Jefferies Downgrades Zoetis to Hold, Lowers Price Target to $83
20.10.2026 08:09
Jefferies analyst Keith Devas downgrades Zoetis (NYSE:ZTS) from Buy to Hold and lowers the price target from $103 to $83.
Zoetis (ZTS) Hit by Guidance Cuts, Met with Market Shrug
15.10.2026 16:04
Middle Coast Investing, an investment advisor firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Market breadth in Q3 2026 reviews shows dominance by a few sectors, with S&P 500 stocks averaging a 9.7% return and only 40.55% above their 200-day moving average. Key themes include AI, inflation, and the U.S.-Iran conflict, […]
3 Reasons ZTS is Risky and 1 Stock to Buy Instead
15.10.2026 13:44
Zoetis has gotten torched over the last six months - since April 2026, its stock price has dropped 37.6% to $75.34 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Zoetis (NYSE:ZTS): A Quality Investing Case Study in Animal Health
14.10.2026 11:21
Zoetis quality investing analysis: high ROIC, strong cash flow, low debt, reasonable valuation, but revenue growth lags Caviar Cruise screen criteria.
Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In Focus
14.10.2026 07:09
Board appointment and dividend set the stage for Zoetis Zoetis (ZTS) has given investors fresh governance and income headlines in October, with Iris Knobloch joining the Board and a fourth quarter dividend of $0.53 per share affirmed. For context, Zoetis shares trade at US$74.30 after a 4.16% 7-day share price gain. However, the 1-year total shareholder return has declined 47.21% and the 5-year total shareholder return is down 61.56%, suggesting recent momentum is tentative against a weaker...
Zoetis (NYSE:ZTS): A Quality Dividend Stock for Income Investors With Room to Grow
09.10.2026 09:40
Zoetis is a dividend stock with strong profitability, low payout ratio, and 20.56% dividend growth, but slower earnings remain a risk.
Neogen Soars 4% as Q1 Revenue Beat and Raised Guidance Show “Encouraging Progress”
07.10.2026 13:34
Key TakeawaysNeogen shares jumped 4% after fiscal first-quarter revenue of $222. 8 million beat the $208.
Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?
02.10.2026 02:49
Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]
Zoetis: Priced For The Worst, Worth Buying
30.09.2026 06:31
Zoetis (ZTS) stock: why shares fell 71% and whatâs next. Margin strength, pipeline vs. 2030+ patent risks, and $113 fair value.
Zoetis (NYSE:ZTS) Looks Like a Decent Value Stock
25.09.2026 09:21
Zoetis (ZTS) screens as decent value: low P/E, strong 9/10 profitability, solid ROIC, and a sustainable dividend, though growth and leverage are risks.
Zoetis: The Worst May Be Priced In
18.09.2026 10:14
Zoetis is still generating the bigger part of its revenue in the United States, the picture for the overall market is different. Read why ZTS stock is a buy.
Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views
18.09.2026 08:13
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay...
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
18.09.2026 05:02
Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kri
Zoetis: Companion Animal Weakness Keeps Me On The Sidelines
17.09.2026 07:20
Zoetis (ZTS) outlook: Q2 2026 revenue flat, U.S. companion animal sales -11%.
Zoetis: An Undervalued Compounder Hiding In Plain Sight
17.09.2026 05:52
Zoetis faces near-term pressure from weaker US companion animal demand, increased competition, and margin compression. Learn more about ZTS stock now.